Renaissance Technologies’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$23.4M Buy
+748,300
New +$18.5M 0.03% 637
2025
Q4
Sell
-55,300
Closed -$465K 3764
2025
Q3
$465K Sell
55,300
-10,200
-16% -$69K ﹤0.01% 2828
2025
Q2
$335K Sell
65,500
-109,000
-62% -$270K ﹤0.01% 3003
2025
Q1
$239K Buy
174,500
+153,000
+712% +$376K ﹤0.01% 3011
2024
Q4
$66.4K Buy
+21,500
New +$99.8K ﹤0.01% 3348
2024
Q2
Sell
-65,600
Closed -$521K 3961
2024
Q1
$521K Sell
65,600
-55,400
-46% -$594K ﹤0.01% 2846
2023
Q4
$1.2M Buy
121,000
+82,800
+217% +$719K ﹤0.01% 2282
2023
Q3
$430K Sell
38,200
-40,500
-51% -$247K ﹤0.01% 2781
2023
Q2
$261K Buy
78,700
+17,800
+29% +$64K ﹤0.01% 3189
2023
Q1
$241K Buy
60,900
+35,600
+141% +$207K ﹤0.01% 3203
2022
Q4
$183K Buy
25,300
+14,100
+126% +$99.2K ﹤0.01% 3448
2022
Q3
$41K Buy
+11,200
New +$47.8K ﹤0.01% 3802

Other funds holding TNGX

Renaissance Technologies's TNGX Position: Q2 2026 in Review

Renaissance Technologies opened a new position in Tango Therapeutics (TNGX) in Q2 2026: 748,300 shares worth $23.4M. The stake represents 0.03% of the portfolio and ranks #637 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in TNGX as recently as Q3 2025.

Renaissance Technologies first reported a position in TNGX in Q3 2022 and has held it in 12 quarters since. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Renaissance Technologies held 748,300 shares of Tango Therapeutics worth $23.4M as of Q2 2026.
  • Tango Therapeutics was a new Renaissance Technologies position in Q2 2026.
  • Tango Therapeutics made up 0.03% of Renaissance Technologies's portfolio in Q2 2026, its #637 holding.
  • Renaissance Technologies first reported a position in Tango Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.